The library

Everything we publish, in one place. Every claim on every page cites a named primary source; where the honest answer is an absence, the absence is printed rather than filled in.

medications A–Z

37 medications — each page carries the FDA approval journey with label quotes, safety signals with the caveats above the numbers, and who pays for prescriptions (Medicare, Medicaid, and the commercial absence).

drug alerts — follow one drug by email and hear when its label, a regulator or a major trial changes something

why fda removed the glp-1 suicide warning — the january 2026 label change on semaglutide, liraglutide and tirzepatide, what fda reviewed, and the studies on both sides

supplements & unapproved substances

17 substances people buy without a prescription. Each page leads with the verbatim regulatory paragraph (sold under DSHEA, never reviewed for effectiveness, dose in the capsule unverified, approved for nothing), then the studies, then the risks, then what the research does not cover. Where the honest finding is futility rather than danger, the page says so.

  • 5-HTP — What the trials show, and the serotonergic interactions that make it a pharmacist question
  • Ashwagandha — The anxiety and stress trials, and the liver-injury reports
  • Cannabidiol (CBD) — The anxiety evidence, the dose gap, and the liver signal
  • Cannabis and THC — What the controlled evidence shows, separated from the policy argument
  • Creatine — The depression syntheses, and why a raised creatinine reading is not kidney damage
  • Kratom — Opioid pharmacology, dependence, and what the human evidence actually is
  • L-Theanine — Nine small trials, none in a diagnosed anxiety disorder, and one null pooled estimate
  • Magnesium — What the trials measured, and what deficiency correction does and does not tell you
  • Melatonin — The sleep evidence, and how much melatonin is actually in the bottle
  • Methylene Blue — An MAO-A inhibitor sold as a nootropic, and the serotonin-syndrome record
  • Microdosing — Where placebo control is enforced, most of the benefit disappears
  • N-Acetylcysteine (NAC) — The psychiatric trials, by condition, and where the pooled estimates land
  • Omega-3 — The depression meta-analyses, the EPA/DHA split, and the heterogeneity problem
  • Phenibut — Dependence and withdrawal, from the case record
  • SAMe — The depression trials, and the mania and interaction signals
  • St John’s Wort — The depression trials, and the interaction list that makes it dangerous with other drugs
  • Valerian — A good safety record and an unconvincing efficacy record

Compared, side by side

33 head-to-head pages for the pairs people actually search — comparing the public record only (usage, payers, warnings, litigation), never ranking.

the system, counted

How the headline numbers of mental health are actually produced — prevalence, trial durations, diagnosis counts — with every method break annotated.

follow the money

Who funds the research, the education, the advocacy, and the coverage — from federal filings and the organizations’ own disclosures. Payments are facts, not verdicts; the framing travels with every number.

health questions, answered from primaries

The questions people actually search, answered from trials, labels, and regulators — including the ones where the honest answer is “the evidence is thin.”

glossary

34 plain-English definitions — the vocabulary needed to read medication evidence and litigation coverage precisely, each with a worked example from this site’s own record.

tools

Interactive, free, and no email required.

checked claims

90 things said on podcasts and youtube about psychiatric medication, diagnosis and the health system, taken to the primary record. one verdict per assertion, confirmed as loudly as corrected.

the evidence library

Every study behind the pages above, individually summarized and scored for trust — design, funding, venue, sample size, preregistration.

Browse the scored evidence library → — or start from the blog and our experts.